Recro Pharma (REPH) Tops Q2 EPS by 72c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Recro Pharma Reports Second Quarter 2018 Financial Results
August 7, 2018 7:00 AM EDTMALVERN, Pa., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ: REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today reported financial results for the three months and six months ended June 30, 2018.
Our recent efforts have been focused on addressing the Complete Response Letter (CRL) received in May 2018 from the U.S. Food and Drug Administration (FDA) for the intravenous (IV) meloxicam New Drug Application, said Gerri Henwood, President and Chief Executive Officer of Recro... More
